Latest news with #insulinpump
Yahoo
5 days ago
- Business
- Yahoo
Does This Move Make Medtronic Stock a Buy?
Medtronic's diabetes care unit has grown faster than the rest of its business in recent years. However, the company decided to spin off this segment into a stand-alone corporation. Still, Medtronic has several growth avenues and an impeccable dividend program. 10 stocks we like better than Medtronic › Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its fastest-growing segments. However, the healthcare leader recently announced some news regarding this unit that might surprise some investors. Let's find out more about it and discuss what it means for Medtronic's prospects. Medtronic markets several products within its diabetes care segment. Perhaps its most important line is its insulin pump franchise. One of the latest iterations of this was the MiniMed 780G, which came with several nifty features, including automatic insulin dose corrections. Medtronic also markets continuous glucose monitoring (CGM) systems that allow diabetes patients to keep track of their blood sugar levels, with constant measurements every few minutes. Additionally, it offers insulin pens and a software that collects information from CGM devices, insulin pumps, and smart pens to create reports to inform patients' progress or share with medical professionals. There is considerable room for growth in the diabetes market. Of the half-billion adults worldwide with diabetes, only 1% had access to CGM technology as of the end of 2023. One might think Medtronic would seize the vast untapped opportunity, especially considering its diabetes care unit's faster growth. During the company's fiscal 2025, ended April 25, Medtronic reported revenue of $33.6 billion, up 3.6% compared to the previous fiscal year. The company's diabetes care segment generated $2.8 billion in sales, with year-over-year growth of 10.7%. True, it still makes up a small part of its business, but given the massive worldwide opportunity, it might have eventually become its biggest growth driver if it kept up its much faster growth pace for a long time. However, Medtronic announced that it would spin off its diabetes care unit, which will become a stand-alone, publicly traded corporation within the next 18 months. Medtronic wants to simplify its portfolio and focus its resources on core, high-margin growth opportunities. That's the rationale management gave for the separation. What does it mean for investors? Medtronic would likely struggle to catch up with the leaders in the diabetes care field. Abbott Laboratories and DexCom dominate the CGM market. In the insulin pump niche, Medtronic has had to compete with companies such as Tandem Diabetes Care. Perhaps Medtronic felt it would not be competitive in these and other niches of the diabetes market over the long run, hence its decision to focus on markets where it "has leading core competencies," to borrow the company's phrasing. While Medtronic will lose its fastest-growing segment, its business should remain robust. The company still markets dozens of products across several other areas that generate consistent revenue and profits. In today's challenging environment, investors tend to gravitate toward steady and stable corporations like Medtronic. Furthermore, the healthcare leader recently announced important news. The company is requesting U.S. clearance for its Hugo robotic-assisted surgery (RAS) system in urologic procedures after the device delivered strong clinical trial results. Approval of Medtronic's RAS Hugo system in the U.S. should unlock massive opportunities, given the industry's underpenetration and significant runway for growth. Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device specialist has increased its dividends for 48 consecutive years -- just two more and it will join the exclusive rank of Dividend Kings. Even with the potential impact of tariffs, Medtronic has performed relatively well this year compared to broader equity markets. In the long run, it should be able to mitigate the effects of tariffs, given its diversified business and consistent earnings, which can enable it to shift its manufacturing around. Medtronic remains a top pick for long-term, income-oriented investors despite spinning off its fastest-growing unit. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic, long January 2027 $65 calls on DexCom, short January 2026 $85 calls on Medtronic, and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Does This Move Make Medtronic Stock a Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
Tandem Diabetes and Roche Reach a Patent Settlement
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem's t:slim X2 insulin pump. A hospital room with a patient using a medical device to administer insulin. The deal settles all pending and prospective litigation about two European patents that Roche filed in December 2023, EP 2 196 231 B1 and EP 1 970 677 B1. Over the next four years, Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will pay the remaining $28 million in four equal annual installments after making an initial payment of $8 million. Both businesses have signed a cross-license agreement as part of the settlement, which will be in place for ten years and grant each other non-exclusive, non-sublicensable, non-royalty-bearing, and irrevocable rights for patents of insulin delivery systems. This action ends all ongoing legal proceedings under the Unified Patent Court in France and Germany, including infringement, revocation, and non-infringement declarations. Tandem Diabetes Care, Inc. (NASDAQ:TNDM)'s t:slim X2 pump will remain commercially available due to the agreement, which also lowers both companies' future legal risk. While we acknowledge the potential of TNDM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TNDM and that has 100x upside potential, check out our report about this READ NEXT: and . Disclosure. None.
Associated Press
23-05-2025
- Business
- Associated Press
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--May 23, 2025-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on CONTACT: Investor Relations: June Lazaroff Senior Director, Investor Relations (978) 600-7718 [email protected]: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: DIABETES HEALTH MEDICAL DEVICES SOURCE: Insulet Corporation Copyright Business Wire 2025. PUB: 05/23/2025 06:01 AM/DISC: 05/23/2025 06:01 AM
